������Ƶ

The project, a previously NSBRI-supported project, stands as a landmark accomplishment in the evolution and advancement of space health research, demonstrating how years later,  investment into biomedical innovation can still yield transformative results for both astronauts and patients on Earth. Originally conceived to address mission‑critical risks posed by kidney stones - a potentially dangerous medical condition in space - this work advanced the development of non‑invasive ultrasound technologies capable of detecting, repositioning, and ultimately fragmenting stones in microgravity environments. These innovations provided a radiation‑free diagnostic alternative and a portable therapeutic solution suited to constrained spacecraft medical systems. NSBRI’s foundational support ensured continuity in high‑risk, high‑reward research that bridged laboratory discoveries with operational medical needs identified by NASA. This long‑term collaboration contributed not just to new scientific methods, but to an entirely new paradigm for delivering care in remote and medically austere environments.

This research pipeline ultimately helped propel the breakthrough achievement of FDA 510(k) clearance for , a technology directly descended from the ultrasound propulsion and burst‑wave lithotripsy methods matured under NSBRI and NASA funding. NSBRI initiated and nurtured the research path that made this milestone possible, with NASA picking up support after NSBRI’s closeout to carry the technology into clinical trials and eventual commercial readiness. The FDA clearance not only validates the scientific rigor behind the research but also showcases the real‑world impact of the Center’s investments in medical technologies designed for space. This achievement is widely regarded as a major success story for the space health community, proving that astronaut‑focused medical research can catalyze pioneering commercial medical technologies with global reach.

As deep‑space missions push farther from Earth, reliable medical decision‑making must continue even during communication blackouts. The Center for Space Medicine successfully demonstrated a novel, Earth‑independent clinical decision support system that brings trustworthy medical expertise directly aboard the spacecraft. In this proof‑of‑concept study, a lightweight, offline artificial intelligence system was deployed on standard laptop hardware and anchored to verified NASA medical documentation using retrieval‑augmented generation. When tested against a high‑risk spaceflight scenario, venous thromboembolism (VTE), the system accurately identified onboard diagnostic capabilities and appropriate treatment options, outperforming conventional artificial intelligence (AI) models that lacked space‑specific grounding. By pairing generative AI with authoritative space medicine resources and eliminating reliance on cloud connectivity, this successful work shows how locally deployed AI can strengthen crew autonomy, reduce clinical risk, and enable safer long‑duration exploration, highlighting the Center’s leadership in translating cutting‑edge research into mission‑ready healthcare solutions.